TIROFIBAN HCL

Tirofiban hydrochloride (HCl) received U.S. Food and Drug Administration (FDA) approval on June 3, 1998.

Tirofiban hydrochloride (HCl) is an antiplatelet medication with multiple clinical applications. Its primary uses include managing acute coronary syndromes (ACS), encompassing unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI), by reducing the risk of coronary artery clot formation. During percutaneous coronary interventions (PCI) like angioplasty and stent placement, it prevents platelet aggregation and clot formation at the intervention site. Additionally, it is occasionally considered for managing thrombocytopenia, investigated for ischemic stroke cases, used in some coronary artery bypass grafting (CABG) procedures to minimize graft occlusion risk, and employed adjunctively in high-risk patients prone to clot formation.

Tirofiban hydrochloride (HCl) is typically administered intravenously (IV), giving it directly into a vein. It is usually administered in a healthcare setting, such as a hospital, where medical professionals can closely monitor the patient.

Tirofiban hydrochloride (HCl) can cause various side effects, ranging from common to serious. Common side effects may include bleeding at the injection site, nausea, headache, fever, and mild chest discomfort. On the other hand, serious side effects, which require immediate medical attention, encompass severe bleeding events, thrombocytopenia (a decrease in platelet count), and allergic reactions with symptoms like rash, swelling, difficulty breathing, and low blood pressure. While less common, tirofiban may lead to back pain or chest pain.

Tirofiban hydrochloride (HCl) significantly increases the risk of bleeding, ranging from minor bleeding at the injection site to more severe events, including gastrointestinal bleeding or intracranial hemorrhage. Anaphylactic reactions are rare but can be life-threatening. It can cause a decrease in platelet counts (thrombocytopenia). Severe thrombocytopenia can increase the risk of bleeding.

Tirofiban hydrochloride (HCl) should be used cautiously in patients with a history of bleeding disorders, recent surgery, or trauma. Close monitoring of bleeding parameters, such as platelet counts and signs of bleeding, is essential during treatment. If any signs of an allergic reaction occur, treatment should be discontinued, and immediate medical attention should be sought. Platelet counts should be monitored regularly during treatment, and the medication should be discontinued if significant thrombocytopenia occurs.

Tirofiban hydrochloride (HCl) requires cautious use due to increased bleeding risk. Patients with bleeding disorders, recent surgery, or a tendency to bleed easily should maintain vigilance. Monitoring for allergic reactions, hypotension, and platelet counts is essential, and kidney and liver function should be assessed. Drug interactions, particularly with anticoagulants, require careful management. Pregnant or breastfeeding patients should consult their healthcare provider before using this medication. Platelet function and cardiac monitoring may be necessary during treatment. Awareness of the nearest emergency medical facility is important, and proper intravenous administration is critical.

ADVANZ Pharma, Electronic Medicines Compendium (EMC), [Revised on 24 Aug 2020] [Accessed on 7th September 2023], https://www.medicines.org.uk/emc/product/566/smpc#gref Medicare Pharma, Inc., US Food and Drug Administration, [Revised on August 2016 ] [Accessed on 7th September 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020912s024,020913s022lbl.pdf